Navigation Links
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Date:9/3/2008

SAN FRANCISCO, Sept. 3 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., a privately-held company focused on developing novel protein therapeutics that selectively target chemokine-activated leukocytes that are responsible for initiating and maintaining inflammatory diseases, announced today that the company has raised $11 million in its first round of venture capital funding. The financing was led by Burrill & Company with participation from Novo Nordisk Biotech Fund (Novo Nordisk's internal corporate venture fund), Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital, Inc. and Western Technology Seed Investment Fund.

"With a lead compound poised to enter clinical studies and a rich pipeline of highly specific protein therapeutics designed to target chemokine-mediated inflammation, we are enthusiastic about the opportunity to invest in Osprey Pharmaceuticals U.S.A.," said John E. Hamer, Ph.D., Managing Partner of Burrill & Company on behalf of the company's investors. "The company has acquired a powerful drug discovery platform which has the potential to yield new high value therapeutics against inflammatory and autoimmune disease."

Osprey Pharmaceuticals U.S.A. will deploy these funds to advance the company's lead product, a therapeutic fusion protein known as CCL2-LPM, into a safety and proof-of-concept clinical trial. CCL2-LPM is designed to target the CCL2-CCR2 chemokine ligand and receptor axis, which play a significant role in inflammatory kidney diseases and other autoimmune and inflammatory conditions. Proceeds will also be applied to the discovery and development of additional therapeutics that have emerged from the company's proprietary platform for the discovery of therapeutic Leukocyte Population Modulators (LPMs). LPMs specifically target chemokine-activated leukocytes that drive and/or maintain a variety of inflammatory and autoimmune disorders.

"We are pleased to have received strong support
'/>"/>

SOURCE Osprey Pharmaceuticals U.S.A., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Osprey Pharmaceuticals Names Jack M. Anthony as CEO
2. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Portal Solutions , a technology ... Microsoft Office 365 and SharePoint platforms , today announces ... for being one of the region’s fastest-growing mid-sized companies based ... , “To be recognized a second year in a ...
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart ... 2014 was a record-breaking year across the board for the ... Smart Data Platform and our Smart Data solutions, our customers ... data which led to record growth for the company in ...
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
... Expands Global Reach with Vietnam Facility ... Corporation, a global leader in specialty diagnostic devices, ... capacity and expanded its worldwide network by opening ... produce and distribute medical devices that are in ...
... PALO ALTO, Calif., April 13 Cell Biosciences, Inc., ... researchers, today announced the publication of a landmark study ... School of Medicine. Dr. Dean W. Felsher, Associate Professor ... publication, titled "Nano-fluidic proteomic assay for serial analysis of ...
... Medical Design Excellence Award(R)MINNEAPOLIS, April 13 Vertebral ... manufacturer announced today the InterFuse(R) Interbody Fusion System ... (MDEA) recipient. "Vertebral Technologies is pleased that ... prestigious award. VTI,s engineering team designed an innovative ...
Cached Biology Technology:Alpine Biomed Opens New Manufacturing Facility to Support Demand for Specialty Diagnostic Devices 2Alpine Biomed Opens New Manufacturing Facility to Support Demand for Specialty Diagnostic Devices 3Cell Biosciences Announces Publication in Nature Medicine 2Vertebral Technologies Receives Award for InterFuse(R) Interbody Fusion System 2
(Date:1/22/2015)... Hall E -   EyeLock Inc. , a market leader ... its EyeLock ID technology integrated in a 3D printed automobile ... Ridge National Laboratory (ORNL) at the 2015 North ... is being used to validate the driver and authorize the ...
(Date:1/22/2015)... Conn. , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: ... mobile commerce market, reports on the recent success of the Wocket™ smart ... Wocket smart wallet was named as one of the "11 ... the "5 Best Products Launched At CES So Far" by Newseveryday.com and ...
(Date:1/22/2015)... , Europe,s most prestigious innovation ... to present a video retrospective of the most exciting and innovative ... Toumazou and Sophie Wilson   A different ...   Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... Microbiology (ASM) has endorsed the One Health Initiative, ... environmental health and seeks to enhance communication, cooperation, ... health and well-being of all species. ... consistent with the ASM mission of applying and ...
... For more than 25 years, the book Histological ... resource for researchers, students, and technologists in the biological ... diseased tissues for microscopic analysis. A new edition, ... remain as the leading source of guidance on the ...
... New Rochelle, NY, May 13, 2008Gene therapy to replace the ... fatal by age 8-12 years, was able to slow significantly ... a paper published online ahead of print in the May ... a peer-reviewed journal published by Mary Ann Liebert, Inc. The ...
Cached Biology News:American Society for Microbiology supports 'One Health' initiative 2Expanded histology methods book covers processing of animal, plant, and microbial tissues 2Gene therapy slows progression of fatal neurodegenerative disease in children 2